IL-6-encoding tumor antigen generates potent cancer immunotherapy through antigen processing and anti-apoptotic pathways

Molecular Therapy

Volumn 15, Issue 10, 2007, Pages 1890-1897

  Hsieh, Chang Yao ^a   Chen, Chi An ^a   Huang, Chia Yen ^a   Chang, Ming Cheng ^a   Lee, Chien Nan ^a   Su, Yi Ning ^a   Cheng, Wen Fang ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN MCL 1; TUMOR ANTIGEN; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CELL BASED GENE THERAPY; CELL SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG POTENCY; EXPRESSION VECTOR; FEMALE; GENETIC TRANSDUCTION; HUMAN PAPILLOMAVIRUS TYPE 16; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTIGENS, NEOPLASM; APOPTOSIS; BASE SEQUENCE; DNA PRIMERS; FEMALE; HUMANS; IMMUNITY, CELLULAR; INTERLEUKIN-6; MICE; MICE, INBRED C57BL; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA;

HUMAN PAPILLOMAVIRUS; MUS;

EID: 34548807539     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300243     Document Type: Article

References (41)

1. Boon, T, Cerottini, JC, Van den Eynde, B, van der Bruggen, P and Van Pel, A (1994). Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12: 337-365.
2. Condon, C, Watkins, SC, Celluzi, CM, Thompson, K and Falo, LD Jr. (1996). DNA-based Immunization by in vivo transfection of dendritic cells. Nat Med 2: 1122-1128.
3. Cheng, WF, Hung, CF, Chai, CY, Hsu, KF, He L, Ling, M et al. (2001). Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 108: 669-678.
4. Chen, CH, Wang, TL, Hung, CF, Yang, Y, Young, RA, Pardoll, DM et al. (2000). Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 60: 1035-1042.
5. Rodriguez, F, Zhang, J and Whitton, JL (1997). DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J Virol 71: 8497-8503.
6. Boyle, JS, Brady, JL and Lew, AM (1998). Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. Nature 392: 408-411.
7. King, CA, Spellerberg, MB, Zhu, D, Rice, J. Sahota, SS, Thompsett, AR et al. (1998). DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 4: 1281-1286.
8. Weiss, WR, Ishii, KJ, Hedstrom, RC, Sedegah, M, Ichino, M, Barnhart K et al. (1998). A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine. J Immunol 161: 2325-2332.
9. Klinman, DM, Yamshchikov, G and Ishigatsubo, Y (1997). Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol 158 3635-3639.
10. +) lymphocytes generated from a DNA vaccine control tumor through the Fas-FasL. pathway. Mol Ther 12: 960-968.
11. Cheng, WF, Chen, LK, Chen, CA, Chang, MC, Hsiao, PN, Su, YN et al. (2006). Chimeric DNA vaccine reverses morphine-induced immunosuppression and tumorigenesis. Mol Ther 13: 203-210.
12. Kim, TW, Hung, CF, Ling, M, Juang, J, He, L, Hardwick, JM et al. (2003). Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest 112: 109-117.
13. Hirano, T (1992). Interleukin-6 and its relation to inflammation and disease. Clin Immunol Immunopathol 62: S60-S65.
14. Tosato, G and Pike, SE (1988). Interferon-beta 2/interleukin 6 is a co-stimulant for human T lymphocytes, J Immunol 141: 1556-1562.
15. Curnow, SJ, Scheel-Toellner, D, Jenkinson, W, Raza, K, Durrani, OM, Faint, JM et al. (2004). Inhibition of T cell apoptosis in the aqueous humor of patients with uveitis by IL-6/soluble IL-6 receptor trans-signaling. J Immunol 173: 5290-5297.
16. Leu, CM, Wong, FH, Chang, C, Huang, SF and Hu, CP (2003). Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene 22: 7809-7818.
17. Cheng, WF, Hung, CF, Chen, CA, Lee, CN, Su, YN, Chai, CY et al. (2005). Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis. Vaccine 23: 3864-3874.
18. Liao, CW, Chen, CA, Lee, CN, Su, YN, Chang, MC, Syu, MH et al. (2005). Fusion protein vaccine by domains of bacterial exotoxin linked with a tumor antigen generates potent immunologic responses and antitumor effects. Cancer Res 65: 9089-9098.
19. Hung, CF, Cheng, WF, Hsu, KF, Chai, CY, He, L, Ling, M et al. (2001). Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 61: 3698-3703.
20. + T cells. J Exp Med 185: 461-469.
21. Kim, TW, Hung, CF, Boyd, DA, He, L, Lin, CT, Kaiserman, D et al. (2004). Enhancement of DNA vaccine potency by coadministration of a tumor antigen gene and DNA encoding serine protease inhibitor-6. Cancer Res 64: 400-405.
22. Kim, TW, Lee, JH, He, L, Boyd, DA, Hardwick JM, Hung, CF et al. Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res 65: 309-316.
23. Reynolds, JE, Yang, T, Qian, L, Jenkinson, JD, Zhou, P, Eastman, A et al. (1994). Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells. Cancer Res 54: 6348-6352.
24. Gross, A, McDonnell, JM and Korsmeyer, SJ (1999). BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13: 1899-1911.
25. Jourdan, M, Veyrune, JL, De Vos, J, Redal, N, Couderc, G and Klein, B (2003). A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene 22: 2950-2959.
26. Brunda, MJ, Luistro, L, Warrier, RR, Wright, RB, Hubbard, BR, Murphy, M et al. (1993). Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 173: 1223-1230.
27. Mederna, JP, Schuurhuis, DH, Rea, D, van Tongeren, J, de Jong, J, Bres, SA et al. (2001). Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: Differential modulation by T helper type 1 and type 2 cells. J Exp Med 194: 657-667.
28. Harper, DM, Franco, EL, Wheeler, CM, Moscicki, AB, Romanowski, B, Roteli-Martins, CM et al. (2006). Sustained efficacy up to 45 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet 367: 1247-1255.
29. Koutsky, LA, Ault, KA, Wheeler, CM, Brown, DR, Barr, E, Alvarez, FB et al. (2002). A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347: 1645-1651.
30. Nichols, WW, Ledwith, BJ, Manam, SV and Troilo, PJ (1995). Potential DNA vaccine integration into host cell genome. Ann NY Acad Sci 772 30-39.
31. Chen, CH, Ji, H, Suh, KW, Choti, MA, Pardoll, DM and Wu, TC (1999). Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the river and lungs Gene Ther 6: 1972-1981.
32. Hung, CF, Cheng, WF, Hsu, KF, Chai, CY, He, L, Ling, M et al. (2001). Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 61: 3698-3703.
33. Feltkamp, MC, Smits, HL, Vierboom, MP, Minnaar, RP, de Jongh, BM, Drijfhout, JW et al. (1993). Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23: 2242-2249.
34. Tindle, RW, Fernando, GJ, Sterling, JC and Frazer, JH (1991). A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proc Natl Acad Sci USA 88: 5887-5891.
35. Cheng, WF, Hung, CF, Hsu, KF, Chai, CY, He, L, Ling, M et al. (2001). Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments. Hum Gene Ther 12: 235-252.
36. Lin, KY, Guamieri, FG, Staveley-O'Carroll, KF, Levitsky, HI, August, JT, Pardoll, DM et al. (1996). Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56: 21-26.
37. Cheng, WF, Hung, CH, Chai, CY, Hsu, KF, He, L, Ling, M et al. (2001). Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen. J Virol 75: 2368-2376.
38. Dialynas, DP, Quan, ZS, Wall, KA, Pierres, A, Quintas, J, Loken, MR et al. (1983). Characterization of the murine T cell surface molecule, designated L3T4; identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. J Immunol 131: 2445-2451.
39. Sarmiento, M, Glasebrook, AL and Fitch, FW (1980). IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement. J Immunol 125: 2665-2772.
40. Koo, GC, Dumont FJ, Tutt, M, Hackett, J Jr. and Kumar, V (1986). The NK-1.1(-) mouse: A model to study differentiation of murine NK cells. J Immunol 137: 3742-3747.
41. Cheng, WF, Lee, CN, Su, YN, Chang, MC, Hsiao, WC, Chen, CA et al. (2005). Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations. Immunology 115: 136-149.